Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Corporate VC Arm of Asian Pharmaceutical Group Invests Up to $20M in Therapeutics Companies, Helps Overseas Companies with Expansion Into Asia

16 Sep

The corporate venture of a publicly listed pharmaceutical group in Asia has successfully invested and established 7 IPO companies in Taiwan and Hong Kong. The firm now focuses on strategic investments which can synergize with its portfolio companies or future business. The firm is open to consider investment opportunities globally, and is willing to help overseas portfolio companies enter into Asia through licensing or joint venture activities. Typical allocation size can range from US$3-20 million.

The firm is investing strategically in selected sectors. Within therapeutics, the firm considers in companies with technology platforms in cell therapy, RNA therapies, bispecific and ADC drugs.  Investment stage can range from preclinical to early clinical stage.  The firm is also interested in investing in early stage CDMO companies in the areas above.


The firm is looking for experienced management teams with proven track records. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Arm of Biotech Holding Company Seeks Global, Pre-Clinical Therapeutics Opportunities with Strong Interests in Small Molecule Modalities

16 Sep

The investment division of a publicly traded biotech company is solely dedicated to the identification and success of early-stage, biotech start-ups for the company’s incubation and investment platforms. The company’s commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

The investment division firm invests globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. Leveraging the parent company’s experience and technical advantages in the field of novel drug R&D, the firm provides both cash and in-kind services (EFS) for their investment. Additionally, based on the need, the firm also offers value-added services in operation and logistic support, BD and Financing assistance, etc. to accelerate the growth of its portfolio companies. The firm can allocate from $500,000 to $5,000,000 of equity capital or convertible notes in seed or Series A.

The firm focuses on novel, preclinical therapeutics and is agnostic to indication, modality and geography. The firm is currently most interested in small molecule first-in-class drugs but is open to considering all drug types. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Diagnostics, Medical Devices, or Healthcare IT companies.

The firm does not have specific requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Life Science VC Invests Up to $10M in Therapeutics, Medical Device, and Diagnostics Companies in North America & Western Europe

16 Sep

A USA-based Life Sciences investment firm typically allocates up to $4M in projects. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach and often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities in the US and Canada, and Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices and diagnostics. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, health IT, and biosimilars/generics are not of interest.

The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives, the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.

The firm is looking for high-caliber serial entrepreneurs with unmatched track-record of success and strong credibility. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm in USA West Coast Invests Opportunistically in Medical Device, Diagnostics, and Digital Health Companies Across the Globe

16 Sep

A venture capital firm founded in 2020 and based in the West Coast USA is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences with its first fund. The firm is looking to engage in Seed to Series A financing rounds with initial check sizes between $4-8M. The firm will also make sub $1M investments in some cases, and will consider convertible notes for these checks. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. The firm is open to all 3 classes of medical devices.

The firm is open to all types of management teams, however clinical experience in the management team is a plus. The firm typically leads investments will seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot AI Mandate: California-based VC Invests in Novel Technologies Across All Sectors of Life Sciences

14 Sep

A San Francisco based Venture Capital firm founded in 2016 is focused on early-stage healthcare companies. The firm currently has 29 companies in their portfolio, and has a network of family offices and high net worth individuals the firm shares deal flow with. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K in the form of equity or convertible notes. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US-focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication, and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. Bioverge prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: US-based VC Focuses on AI and Machine Learning in Life Sciences Globally

14 Sep

A Venture Capital firm was founded in 2020 and is located in Plano, Texas. The firm is different from a traditional VC in that it focuses on investing, building and scaling life science start-ups. The goal is to co-innovate and grow with the startups they invest in. The firm has a fund that is financed by 35 angels groups as well as a hedge fund. Investments are mainly in the form of equity and in-licensing, but the firm is flexible on a case-by-case basis with convertible notes. The firm has 7 life science companies in their portfolio to date. The firm’s main focus is biotech, medtech, and AI and machine learning technologies. Bio 9 Ventures’ goal is to build innovations in hospitals that transform the lives of patients and make doctors jobs easier. The firm focuses on Pre-Seed, Seed and Series A financing rounds. Bio 9 Ventures is open to global opportunities.

The firm focuses on AI, machine learning, and other biotech/medtech technologies, and within those domains, are open to all 4 main sectors. The firm looks for technologies in: consumer health, connected health practices, patient engagement related arenas, telehealth, distal therapeutics, and consumer health solutions and services. The firm doesn’t focus on traditional medical devices, but is looking to invest in “smart” medical devices that support connected health practices. The firm is open to most indications, especially oncology, women’s health, mental health, respiratory, cardiology, and pediatrics. The firm is not interested in drugs therapeutics or immunology with the exception of mRNA vaccines. The firm invests in pre-clinical companies.

The firm is looking for a team that they can work and co-innovate with and do channel partnering with to scale their businesses. For this firm, the concept or idea is the most important part and they are looking for more than what companies built today, they look for the future impact. Interested companies should have management teams that are in alignment with the firm’s values and that their end outcome is patient success. The firm can lead or co-invest on a case by case basis and will seek board seat representation on a case by case basis as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: UK-based VC Invests Pre-seed/seed Capital Into Therapeutics Early-stage Companies

14 Sep

A venture builder founded in 2016 and headquartered in London, United Kingdom seeks to build new ventures from scratch, generating innovation in novel science and technology from the earliest stages of development. Currently, the firm is focused on 4 main pillars: energy, agriculture, curative therapeutics, and computation. The firm invests pre-seed/seed capital into the companies they build. The firm will consider global opportunities.

Within life sciences, the firm is indication agnostic and has worked in areas including cystic fibrosis, oncology, neurodegeneration and microbiome. The firm has partnered with groups such as the Cystic Fibrosis Foundation and Cancer Research UK to devise new therapeutic approaches in their key focus areas. The firm has a strong interest in cell & gene therapy and synthetic biology, but is open to considering all other modalities – the firm has also launched companies that work on a more traditional approach.

In terms of stage of development, the firm invests in the companies it builds at formation stage and is open to working together with other organisations to undertake company creation and support proof-of-concept data generation. The firm generally does not currently build, or invest in, medical devices, diagnostics, or digital health companies.

As a venture builder, the firm does not have strict requirements or expectations on company operations or management team. The firm has generally built companies in the UK. That said, the firm has worked with scientists all across the globe to build its companies, and their portfolio also includes companies in other geographies such as the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

%d bloggers like this: